LECT 2 Antagonizes FOXM1 Signaling via Inhibiting MET to Retard PDAC Progression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited treatment options.
• There is a critical need for novel biomarkers and therapeutic targets for PDAC.
• Understanding the molecular mechanisms driving PDAC progression is essential.

Purpose of the Study:

• To elucidate the role of leukocyte cell-derived chemotaxin-2 (LECT2) in pancreatic ductal adenocarcinoma (PDAC) development.
• To investigate LECT2 as a potential biomarker and therapeutic target for PDAC.

Main Methods:

• In vitro cell culture models were used to assess LECT2's effects on PDAC cell behavior.
• In vivo animal models were employed to study LECT2's impact on tumor growth and metastasis.
• Molecular analyses were performed to determine the signaling pathways affected by LECT2.

Main Results:

• LECT2 expression is significantly downregulated in metastatic PDAC compared to primary tumors.
• LECT2 absence correlates with advanced clinical features and poor prognosis.
• LECT2 overexpression suppressed PDAC cell proliferation, epithelial-mesenchymal transition, migration, and invasion in vitro and inhibited tumor growth and lung metastasis in vivo.
• Mechanistically, LECT2 inhibits FOXM1 signaling via the HGF/MET pathway, thereby retarding PDAC progression.

Conclusions:

• LECT2 plays a crucial role in suppressing PDAC progression.
• LECT2 functions as a tumor suppressor by inhibiting key oncogenic signaling pathways.
• LECT2 represents a promising biomarker and a potential therapeutic target for pancreatic ductal adenocarcinoma.